[Randomized, comparative study to evaluate efficacy and safety of doxazosin versus nitrendipine in the treatment of mild to moderate hypertension].
Doxazosin, an alfa-1 adrenoceptor antagonist, was compared with nitrendipine, a calcium antagonist, to evaluate their efficacy and safety in 61 patients with mild to moderate hypertension. 31 patients were assigned randomly to receive 1-16 mg of doxazosin and 30 patients were assigned to 10-20 mg of nitrendipine during 14 weeks (10 weeks of titration and 4 weeks of maintenance). Mean final dose was 6.1 mg for doxazosin and 15.6 mg for nitrendipine. Both treatments reduced supine and standing diastolic and systolic blood pressure (p < 0.01 for all comparisons). 22 patients in the doxazosin group (78.6%) and 18 in the nitrendipine group (78.3%) were considered therapy successes. There were not clinically significant changes in laboratory tests for both groups. Global assessment of adverse events was similar for both treatments (46.7% for doxazosin and 44.8% for nitrendipine), although patients treated with nitrendipine presented facial rush (20%) against none of the doxazosin group (p < 0.05). Withdrawals due to adverse events were higher in the nitrendipine group than in the doxazosin one (20.7% versus 6.7%, p = 0.14). The results of this study confirms that both antihypertensives reduced blood pressure in patients with mild to moderate hypertension. Furthermore, doxazosin treatment demonstrates a fewer number of withdrawals caused by adverse events.
Sanz Guajardo
D
D
Servicio de Nefrología, Clínica Puerta de Hierro, Laboratorios Pfizer, S.A. Madrid.
Espejo Martínez
J
J
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D017292:Doxazosin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009568:Nitrendipine / Q000627:therapeutic use*
D000317:Adrenergic alpha-Antagonists; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D009568:Nitrendipine; D017292:Doxazosin
Estudio randomizado, comparativo, sobre la eficacia y seguridad de doxazosina frente a nitrendipino en el tratamiento de la hipertensión arterial ligera a moderada.